Abstract
Background and Aims
Patients with inflammatory bowel disease (IBD) often have subjective symptoms for months or years prior to their diagnosis. Blood tests taken prior to diagnosis may provide objective evidence of duration of pre-diagnosis disease. We aim to describe the pre-diagnosis laboratory pattern of patients with IBD.
Methods
A total of 838 patients diagnosed with IBD between 01/01/1996 and 01/03/2014, with pre-diagnosis laboratory testing available, contributed data for analysis. C-reactive protein, erythrocyte sedimentation rate, hemoglobin level, mean cell volume (MCV) platelet count, white blood cell count, neutrophil count, albumin level, ferritin level, serum iron level, alanine transaminase level, and fecal calprotectin were examined in the 24 months leading up to diagnosis and compared to baseline data taken between 24 and 36 months prior to diagnosis.
Results
For patients with Crohn’s disease, a significant drop in serum albumin and MCV levels and a significant rise in platelet count were observed between 115 and 385 days prior to diagnosis (p < 0.01, two-tailed t test). For patients with ulcerative colitis, a significant change in albumin level, MCV, hemoglobin level, platelet count, and serum iron level was observed at diagnosis (p < 0.01, two-tailed t test) but was not detectable before.
Conclusions
These data provide objective evidence of duration of delay between disease onset and diagnosis in a cohort of patients with IBD. Expediting diagnostic testing in patients presenting with symptoms consistent with IBD, who also have abnormal laboratory results, may reduce diagnostic delay, speed access to therapy, and improve clinical outcomes.
Similar content being viewed by others
Abbreviations
- ALT:
-
Alanine transaminase
- CRP:
-
C-reactive protein
- ESR:
-
Erythrocyte sedimentation rate
- IBD:
-
Inflammatory bowel diseases
- MCV:
-
Mean cell volume
- WBC:
-
White blood cell count
References
Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2–6.
Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohns Colitis. 2010;4:7–27. https://doi.org/10.1016/j.crohns.2009.12.003.
Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohns Colitis. 2010;4:28–62. https://doi.org/10.1016/j.crohns.2009.12.002.
Tedesco FJ, Hardin RD, Harper RN, Edwards BH. Infectious colitis endoscopically simulating inflammatory bowel disease: A prospective evaluation. Gastrointest Endosc. 1983;29:195–197.
Schumacher G, Sandstedt B, Kollberg B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Clinical findings and early diagnosis. Scand J Gastroenterol. 1994;29:265–274.
Vavricka SR, Spigaglia SM, Rogler G, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:496–505. https://doi.org/10.1002/ibd.21719.
Nguyen VQ, Jiang D, Hoffman SN, et al. Impact of diagnostic delay and associated factors on clinical outcomes in a U.S. inflammatory bowel disease Cohort. Inflamm Bowel Dis. 2017;23:1825–1831. https://doi.org/10.1097/mib.0000000000001257.
Sorrentino D. Preclinical and undiagnosed Crohn’s disease: The submerged Iceberg. Inflamm Bowel Dis. 2016;22:476–486. https://doi.org/10.1097/MIB.0000000000000612.
Choung RS, Princen F, Stockfisch TP, et al. Serologic microbial associated markers can predict Crohn’s disease behaviour years before disease diagnosis. Aliment Pharmacol Ther. 2016;43:1300–1310. https://doi.org/10.1111/apt.13641.
Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease. Gut. 2004;53:1117–1122. https://doi.org/10.1136/gut.2003.030734.
Israeli E, Grotto I, Gilburd B, et al. Anti-saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232–1236. https://doi.org/10.1136/gut.2004.060228.
Lochhead P, Khalili H, Ananthakrishnan AN, Richter JM, Chan AT. Association between circulating levels of C-reactive protein and Interleukin-6 and risk of inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2016;14:818–824.e6. https://doi.org/10.1016/j.cgh.2016.01.016.
Karlson EW, Chibnik LB, Tworoger SS, et al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum. 2009;60:641–652. https://doi.org/10.1002/art.24350.
Aho K, Heliövaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol. 1991;18:1282–1284.
del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum. 1988;31:1239–1244.
Jónsson T, Thorsteinsson J, Kolbeinsson A, Jónasdóttir E, Sigfússon N, Valdimarsson H. Population study of the importance of rheumatoid factor isotypes in adults. Ann Rheum Dis. 1992;51:863–868.
Verge CF, Gianani R, Kawasaki E, et al. Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes. J Autoimmun. 1996;9:379–383.
R Core Team. R: A Language and Environment for Statistical Computing, R version 3.4.4. Vienna, Austria: R Foundation for Statistical Computing; 2018. https://www.R-project.org/. Accessed 12 Nov 2018.
Zeileis A, Grothendieck G. zoo: S3 Infrastructure for regular and irregular time series. J Stat Softw. 2005;14:1–27. https://doi.org/10.18637/jss.v014.i06.
Champely S. PWR: Basic Functions for Power Analysis, R package version 1.2-1; 2017. https://CRAN.R-project.org/package=pwr. Accessed 12 Nov 2018.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale: L. Erlbaum Associates; 1988.
Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA. Gender-related differences in the clinical course of Crohn’s disease. Am J Gastroenterol. 2001;96:1541–1546. https://doi.org/10.1111/j.1572-0241.2001.03755.x.
Bager P, Befrits R, Wikman O, et al. The prevalence of anemia and iron deficiency in IBD outpatients in Scandinavia. Scand J Gastroenterol. 2011;46:304–309. https://doi.org/10.3109/00365521.2010.533382.
OECD Statistics. http://stats.oecd.org/. Accessed June 20, 2017.
Sørensen J, Hetland ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2015;74:e12. https://doi.org/10.1136/annrheumdis-2013-204867.
Inflammatory bowel disease|Guidance and guidelines|NICE. https://www.nice.org.uk/guidance/qs81. Accessed June 21, 2016.
English|World Gastroenterology Organisation. http://www.worldgastroenterology.org/guidelines/global-guidelines/inflammatory-bowel-disease-ibd/inflammatory-bowel-disease-ibd-english. Accessed June 21, 2016.
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794. https://doi.org/10.1053/j.gastro.2011.01.055.
Radford-Smith G, Pandeya N. Associations between NOD2/CARD15 genotype and phenotype in Crohn’s disease-Are we there yet? World J Gastroenterol WJG. 2006;12:7097–7103. https://doi.org/10.3748/wjg.v12.i44.7097.
Higuchi LM, Khalili H, Chan AT, Richter JM, Bousvaros A, Fuchs CS. A prospective study of cigarette smoking and the risk of inflammatory bowel disease in women. Am J Gastroenterol. 2012;107:1399–1406. https://doi.org/10.1038/ajg.2012.196.
Klement E, Cohen RV, Boxman J, Joseph A, Reif S. Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am J Clin Nutr. 2004;80:1342–1352.
Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25:325–333. https://doi.org/10.1111/j.1440-1746.2009.06140.x.
Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut. 2002;51:808–813.
Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn’s disease. Scand J Gastroenterol. 2008;43:961–966.
Connolly D, Black A, Murray LJ, Napolitano G, Gavin A, Keane PF. Methods of calculating prostate-specific antigen velocity. Eur Urol. 2007;52:1044–1050. https://doi.org/10.1016/j.eururo.2006.12.017.
Heianza Y, Arase Y, Fujihara K, et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: The Toranomon Hospital Health Management Center Study 7 (TOPICS 7). Diabetes Care. 2012;35:1050–1052. https://doi.org/10.2337/dc11-1793.
Funding
This work was supported by peer-reviewed grants from the National Health and Medical Research Council (Australia) and the Royal Brisbane and Women’s Hospital Foundation.
Author information
Authors and Affiliations
Contributions
JRI performed data collection, performed statistical analysis, drafted the manuscript, and was involved in the final review of the manuscript. GRS performed data collection and was involved in the final review of the manuscript. JDD performed statistical analysis and was involved in the final review of the manuscript. EF, KH, LAS, AA, and DL performed data collection and were involved in review of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
GRS has worked on advisory boards for and received consulting fees from Abbvie, Janssen, Ferring, Takeda, and Amgen. JRI, EF, KH, LAS, JD, DL, and AA have no conflict of interest to declare.
Rights and permissions
About this article
Cite this article
Irwin, J.R., Ferguson, E., Simms, L.A. et al. Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn’s Disease. Dig Dis Sci 64, 503–517 (2019). https://doi.org/10.1007/s10620-018-5357-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-018-5357-0